We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $362M
1-Year Est. Return 230.96%
This Fund
S&P 500
This Quarter Est. Return
+15.22%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$280M
AUM Growth
+$4.87M
Cap. Flow
-$17.4M
Cap. Flow %
-6.19%
Top 10 Hldgs %
28.7%
Holding
166
New
40
Increased
28
Reduced
35
Closed
35

Top Buys

Rank Stock Value
1
APGE icon
Apogee Therapeutics
APGE
+$5.21M
2
ANSS
Ansys
ANSS
+$4.33M
3
JNPR
Juniper Networks
JNPR
+$4.19M
4
GDX icon
VanEck Gold Miners ETF
GDX
+$2.49M
5
SWTX
SpringWorks Therapeutics
SWTX
+$2.36M

Top Sells

Rank Stock Value
1
SYRE icon
Spyre Therapeutics
SYRE
+$12.3M
2
IMVT icon
Immunovant
IMVT
+$5.11M
3
IMGN
Immunogen Inc
IMGN
+$4.29M
4
SPLK
Splunk Inc
SPLK
+$4.2M
5
SOVO
Sovos Brands, Inc. Common Stock
SOVO
+$4.07M

Sector Composition

Rank Sector Weight
1 Healthcare 44.78%
2 Technology 11.84%
3 Consumer Discretionary 7.8%
4 Industrials 6.17%
5 Financials 4.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DBC icon
1
Invesco DB Commodity Index Tracking Fund
DBC
$1.69B
$33M 11.76%
1,436,136
– –
APGE icon
2
Apogee Therapeutics
APGE
$10.1B
$7.93M 2.83%
+119,403
New +$5.21M
SYRE icon
3
Spyre Therapeutics
SYRE
$8.54B
$5.86M 2.09%
154,381
-423,235
-73% -$12.3M
MRUS
4
DELISTED
Merus
MRUS
$5.48M 1.95%
121,680
-11,892
-9% -$482K
MSFT icon
5
Microsoft
MSFT
$3.45T
$5.16M 1.84%
12,258
-2,200
-15% -$891K
ACLX
6
DELISTED
Arcellx
ACLX
$5.02M 1.79%
72,230
– –
XPO icon
7
XPO
XPO
$23.6B
$4.68M 1.67%
38,380
+12,400
+48% +$1.33M
NUVL
8
DELISTED
Nuvalent
NUVL
$4.51M 1.61%
60,011
+5,928
+11% +$472K
ANSS
9
DELISTED
Ansys
ANSS
$4.44M 1.58%
+12,800
New +$4.33M
HES
10
DELISTED
Hess
HES
$4.41M 1.57%
28,900
– –
IDYA icon
11
IDEAYA Biosciences
IDYA
$3.42B
$4.36M 1.55%
99,292
-27,553
-22% -$1.18M
JNPR
12
DELISTED
Juniper Networks
JNPR
$4.25M 1.52%
+114,700
New +$4.19M
SP
13
DELISTED
SP Plus Corporation
SP
$4.12M 1.47%
78,900
– –
CERE
14
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$4.11M 1.47%
97,200
– –
ACI icon
15
Albertsons Companies
ACI
$5.62B
$4.05M 1.44%
188,753
– –
BCYC
16
Bicycle Therapeutics
BCYC
$269M
$3.94M 1.41%
158,293
– –
AXSM icon
17
Axsome Therapeutics
AXSM
$11.2B
$3.87M 1.38%
48,527
-13,736
-22% -$1.15M
INDV icon
18
Indivior Pharmaceuticals
INDV
$4.73B
$3.82M 1.36%
178,836
+13,995
+8% +$263K
CRM icon
19
Salesforce
CRM
$151B
$3.82M 1.36%
12,679
-2,300
-15% -$664K
AMZN icon
20
Amazon
AMZN
$2.92T
$3.62M 1.29%
20,093
+12,300
+158% +$2.05M
AMED
21
DELISTED
Amedisys
AMED
$3.62M 1.29%
39,250
– –
CPRI icon
22
Capri Holdings
CPRI
$1.83B
$3.52M 1.26%
77,700
– –
VRDN icon
23
Viridian Therapeutics
VRDN
$2.09B
$3.48M 1.24%
198,484
– –
INSM icon
24
Insmed
INSM
$21.4B
$3.44M 1.23%
126,780
– –
XENE icon
25
Xenon Pharmaceuticals
XENE
$6.06B
$3.13M 1.12%
72,715
+20,914
+40% +$962K
1
2 3 4 5

Similar funds

SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WI
WBI Investments Red Bank, New Jersey $362M AUM 23.75% 1-Year Est. Return
BHBT
Burke & Herbert Bank & Trust Alexandria, Virginia $362M AUM 20.5% 1-Year Est. Return
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
RC
Reik & Co New York $363M AUM 3.03% 1-Year Est. Return
VIA
Virtus Investment Advisers Hartford, Connecticut $363M AUM 34.89% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return

HighVista Strategies's Q1 2024 Portfolio in Review

As of Q1 2024, HighVista Strategies held 166 positions worth $280M, up 1.8% from $276M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

HighVista Strategies withdrew a net $17.4M in Q1 2024, closing 35 positions and reducing 35 holdings. Its most notable exit was Immunovant, an estimated $5.11M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 45% of assets, down from 46% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, HighVista Strategies opened a new position in Apogee Therapeutics worth $7.93M.

  • HighVista Strategies's largest Q1 2024 buy was Apogee Therapeutics: 119,403 shares worth $7.93M.
  • HighVista Strategies added most to argenx in Q1 2024, an estimated $2.2M increase.
  • HighVista Strategies's biggest Q1 2024 reduction was Spyre Therapeutics, cutting an estimated $12.3M.
  • HighVista Strategies fully exited Immunovant in Q1 2024, selling an estimated $5.11M.
  • HighVista Strategies's ten largest holdings make up 29% of its $280M portfolio in Q1 2024.
  • HighVista Strategies opened 40 new positions and closed 35 in Q1 2024.
  • HighVista Strategies's portfolio value rose 1.8% quarter-over-quarter to $280M.

Based on HighVista Strategies's 13F filing for Q1 2024, filed 15 May 2024.